Cormorant Asset Management Reports 6.51% Stake in BioAge Labs, Inc. (BIOA)

On May 15, 2026, Cormorant Asset Management, LP and its managing member, Bihua Chen, filed a Schedule 13G/A with the SEC, reporting a 6.51% ownership stake in BioAge Labs, Inc. (BIOA). The reporting persons disclosed beneficial ownership of 2,890,605 shares of Common Stock as of the event date of March 31, 2026. This filing represents an increase from a previously reported 0% position, marking a significant entry or restoration of their holdings in the Emeryville-based biotechnology company. The shares are held directly by various Cormorant Funds, with Cormorant Asset Management acting as the investment adviser and Bihua Chen exercising shared voting and dispositive power over the securities. The filing was made under Rule 13d-1(b), indicating that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. The calculation of the ownership percentage is based on 44,379,753 shares of Common Stock outstanding as of March 19, 2026.